Actively Recruiting
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Led by Wenjin Yin · Updated on 2025-09-11
86
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
CONDITIONS
Official Title
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female, age 18 years or older
- ECOG performance status of 2 or less
- Pathologically confirmed primary breast cancer with recurrent or metastatic lesions confirmed by pathology or radiology
- Hormone receptor and HER2 status: HR+/HER2+, HR-/HER2+, or HR-/HER2-
- At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
- Disease control (complete response, partial response, or stable disease) after salvage treatment
- Expected survival of 6 months or more
- Adequate organ function
You will not qualify if you...
- Currently pregnant or breastfeeding
- Presence of central nervous system metastasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here